IP Library Patent Application 16142394
Patent Application
App. No. 16/142,394

CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/142,394
Abstract

The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.

Claims (16)

1 . A method of treating peripheral neuropathic pain in a patient comprising

administering to a patient in need thereof a therapeutically effective amount of a cannabis based medicinal extract (CBME) comprising cannabidiol (CBD) and tetrahydrocannabinol (THC), wherein the ratio of CBD to THC, by weight, is about 24:1.

2 . The method of treating peripheral neuropathic pain as claimed in claim 1 , wherein the peripheral neuropathic pain is allodynia.

3 - 4 . (canceled)

5 . The method of treating peripheral neuropathic pain as claimed in claim 1 , wherein the CBD and THC are packaged for delivery in a titratable dosage form.

6 . The method of treating peripheral neuropathic pain as claimed in claim 1 , wherein the CBME is packaged such that delivery is targeted to an area selected from the group consisting of: sublingual; buccal; parenteral; oral; rectal, nasal; and the pulmonary system.

7 . The method of treating peripheral neuropathic pain as claimed in claim 6 , wherein the CBME is in the form selected from the group consisting of: gel; gel spray; tablet; liquid; capsule and for vaporisation.

8 . The method of treating peripheral neuropathic pain as claimed in claim 1 , wherein the CBME is formulated as a ratioed product from:

a) a cannabis based medicinal extract which comprises THC at more than 90% of the total cannabinoid content in the extract; and

b) a cannabis based medicinal extract which comprises CBD at more than 90% of the total cannabinoid content in the extract.

9 . The method of treating peripheral neuropathic pain as claimed in claim 1 , further comprising administering to the patient in need thereof a therapeutically effective amount of one or more other medicinal substances.

10 . The method of treating peripheral neuropathic pain as claimed in claim 9 , wherein the one or more other medicinal substances are one or more analgesic drugs.

11 . The method of treating peripheral neuropathic pain as claimed in claim 9 , wherein the one or more other medicinal substances are one or more opiate or opiate related drugs.

12 . The method of treating peripheral neuropathic pain as claimed in claim 9 , wherein the one or more other medicinal substances are one or more anticonvulsant drugs.

13 . The method of treating peripheral neuropathic pain as claimed in claim 9 , wherein the one or more other medicinal substances are one or more antidepressant drugs.

14 . The method of treating peripheral neuropathic pain as claimed in claim 9 , wherein the CBD and THC are administered separately, simultaneously or sequentially to the one or more other medicinal substances.

Assignments (2)
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018
From: GUY, GEOFFREY; COSTA, BARBARA
To: GW PHARMA LIMITED
Reel/Frame 047766/0674 →